Biogen Inc. /
Apellis Pharmaceuticals, Inc.
Biogen completes purchase of Apellis through merger
Source for the buyer and target: Apellis Pharmaceuticals, Inc.
For the buyer and target.
“As previously disclosed, on March 31, 2026, Apellis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Biogen Inc., a Delaware corporation (“Biogen”), and Aspen Purchaser Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Biogen (“Purchaser”).”
Published 14 May 2026
Open the sourceWhat happened
Biogen has finished its acquisition of Apellis Pharmaceuticals, Inc. after a tender offer expired on May 13, 2026, with a large share of shares tendered. The merger took effect on May 14, 2026, and Apellis is now a wholly owned subsidiary of Biogen. [01]
The total amount paid in the offer and merger is approximately $5.3 billion, excluding fees and expenses and any contingent value right payments. [01]
The source
Everything on this page comes from the source below, quoted word for word.
Biogen completes purchase of Apellis through merger
This document is the source for the companies, stage, figure and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
Also stated
“Biogen completes purchase of Apellis through merger Biogen has finished its acquisition of Apellis Pharmaceuticals, Inc. after a tender offer expired on May 13, 2026, with a large share of shares tendered”
Open the sourceClosed
“The merger took effect on May 14, 2026, and Apellis is now a wholly owned subsidiary of Biogen”
Open the source
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly